Head-to-head · WeighScore
Livv vs Renlo Health
By GLP-1 ScorecardUpdated
Score comparison
Renlo Health has the higher recorded score — 79.7/100 to 64.9/100.
Renlo Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. One of the few programs whose headline is the actual monthly rate, with the prescribing physician and the dispensing pharmacy both named.
Before you choose
Before comparing the headline prices, the Livv review and the Renlo Health review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.
If neither one fits, Livv vs Science & Co and Loop Health vs Renlo Health compare each of them with another graded program, and the list of alternatives to Livv ranks the programs closest to Livv on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.
Of the sellers that pay us a commission, the GoodLife Health review covers one graded close to these two, at 69.8/100. That relationship never changes a grade, and the review lists what we could not verify.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | Livv | Renlo Health |
|---|---|---|
| WeighScore | 64.9/100 | 79.7/100 |
| Grade | C | C+ |
| Site position | #247 | #40 |
| Semaglutide | $146/mo monthly plan ($124/mo on 6-month plan; now sold as 50 Stars Health; compounded) | $149/mo at every dose (shown against $299) |
| Tirzepatide | $220/mo monthly plan ($183/mo on 6-month plan; compounded) | $199/mo at every dose (shown against $399) |
| Coverage | Coverage not published | Not publicly listed |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Not confirmed | Not confirmed |
Strengths
- Both semaglutide and tirzepatide available
- Compounded GLP-1 access
What to consider
- Limited public information on program details
Strengths
- The headline is the real month-to-month rate — no prepay division and no commitment behind an asterisk
- A genuine all-in line: medication, injection supplies, provider evaluation, ongoing care, expedited shipping and unlimited care-team messaging, with no membership or consultation fees
- Names the prescribing physician, Dr. Sean Arora, MD, and the dispensing pharmacy, VialsRX
- Same price at every dose with a price-lock badge
- A four-month money-back guarantee, and cancel anytime with no fee
What to consider
- A struck-through $399 sits beside the price with no published basis — Renlo never says what it was, when it applied or to whom
- That strikethrough comes from a stylesheet rule rather than a struck-out element, so a markup-level check would report the page clean
- A comparison table headed "Most GLP-1 providers" quotes $270, $365 and $445 by dose while naming no provider and citing no source
- A site-wide $50 code means the advertised figure is not the first amount charged
- No lab protocol is published, and there is no oral or brand route
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
Commercial relationships affect this placement. The score comparison above is separate.
Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.